GENERAL INTRODUCTION 23 1 70. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerininduced cluster headache attack. Pain. 1995;60(2):119-123. 71. Ashina H, Schytz HW, Ashina M. CGRP in human models of primary headaches. Cephalalgia. 2016;38(2):353-360. 72. Messlinger K, Vogler B, Kuhn A, et al. CGRP measurements in human plasma - a methodological study. Cephalalgia. 2021;41(13):1359-1373. 73. Kuehnbaum NL, Britz-McKibbin P. New advances in separation science for metabolomics: resolving chemical diversity in a post-genomic era. Chem Rev. 2013;113(4):2437-2468. 74. Fiehn O, Robertson D, Griffin J, et al. The metabolomics standards initiative (MSI). Metabolomics. 2007;3(3):175-178. 75. Lehmann R. From bedside to bench-practical considerations to avoid pre-analytical pitfalls and assess sample quality for high-resolution metabolomics and lipidomics analyses of body fluids. Anal Bioanal Chem. 2021;413(22):55675585. 76. Carraro P, Zago T, Plebani M. Exploring the initial steps of the testing process: frequency and nature of pre-preanalytic errors. Clin Chem. 2012;58(3):638-642. 77. Lippi G, Guidi GC, Mattiuzzi C, Plebani M. Preanalytical variability: the dark side of the moon in laboratory testing. Clin Chem Lab Med. 2006;44(4):358-365. 78. Szecsi PB, Ødum L. Error tracking in a clinical biochemistry laboratory. Clin Chem Lab Med. 2009;47(10):1253-1257. 79. Ritchie MD, Holzinger ER, Li R, Pendergrass SA, Kim D. Methods of integrating data to uncover genotype–phenotype interactions. Nature Reviews Genetics. 2015;16(2):85-97. 80. Liu X, Hoene M, Wang X, et al. Serum or plasma, what is the difference? Investigations to facilitate the sample material selection decision making process for metabolomics studies and beyond. Anal Chim Acta. 2018;1037:293-300. 81. Noga MJ, Zielman R, van Dongen RM, et al. Strategies to assess and optimize stability of endogenous amines during cerebrospinal fluid sampling. Metabolomics. 2018;14(4):44. 82. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914-1922. 83. Bar N, Korem T, Weissbrod O, et al. A reference map of potential determinants for the human serum metabolome. Nature. 2020;588(7836):135140. 84. Dallmann R, Viola AU,Tarokh L, Cajochen C, Brown SA. The human circadian metabolome. Proc Natl Acad Sci U S A. 2012;109(7):26252629. 85. Kasukawa T, Sugimoto M, Hida A, et al. Human blood metabolite timetable indicates internal body time. Proc Natl Acad Sci U S A. 2012;109(37):15036-15041. 86. Chua EC, Shui G, Lee IT, et al. Extensive diversity in circadian regulation of plasma lipids and evidence for different circadian metabolic phenotypes in humans. Proc Natl Acad Sci U S A. 2013;110(35):14468-14473. 87. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87(3):543-552. 88. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005;366(9483):371-377. 89. De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003;33(2):192-196. 90. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747-753. 91. Hiekkala ME, Vuola P, Artto V, et al. The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families. Cephalalgia. 2018;38(12):1849-1863.
RkJQdWJsaXNoZXIy MTk4NDMw